NDC 17772-133

QELBREE

Viloxazine Hydrochloride

QELBREE is a Oral Capsule, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Supernus Pharmaceuticals, Inc. The primary component is Viloxazine Hydrochloride.

Product ID17772-133_bfca3279-8f36-5bb2-e053-2995a90a23a5
NDC17772-133
Product TypeHuman Prescription Drug
Proprietary NameQELBREE
Generic NameViloxazine Hydrochloride
Dosage FormCapsule, Extended Release
Route of AdministrationORAL
Marketing Start Date2021-04-02
Marketing CategoryNDA /
Application NumberNDA211964
Labeler NameSupernus Pharmaceuticals, Inc
Substance NameVILOXAZINE HYDROCHLORIDE
Active Ingredient Strength200 mg/1
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 17772-133-01

100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (17772-133-01)
Marketing Start Date2021-04-02
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "QELBREE" or generic name "Viloxazine Hydrochloride"

NDCBrand NameGeneric Name
17772-131QELBREEviloxazine hydrochloride
17772-132QELBREEviloxazine hydrochloride
17772-133QELBREEviloxazine hydrochloride

Trademark Results [QELBREE]

Mark Image

Registration | Serial
Company
Trademark
Application Date
QELBREE
QELBREE
88696469 not registered Live/Pending
Supernus Pharmaceuticals, Inc.
2019-11-18

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.